Lineage Cell Accounts Payable Over Time
| LCTX Stock | USD 0.61 0.04 7.02% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lineage Cell Performance and Lineage Cell Correlation. Lineage |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lineage Cell. If investors know Lineage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lineage Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.10) | Revenue Per Share 0.034 | Quarterly Revenue Growth (0.56) | Return On Assets (0.13) | Return On Equity (0.35) |
The market value of Lineage Cell Therapeutics is measured differently than its book value, which is the value of Lineage that is recorded on the company's balance sheet. Investors also form their own opinion of Lineage Cell's value that differs from its market value or its book value, called intrinsic value, which is Lineage Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lineage Cell's market value can be influenced by many factors that don't directly affect Lineage Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lineage Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lineage Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lineage Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Lineage Cell Therapeutics and related stocks such as MAIA Biotechnology, Armata Pharmaceuticals, and Frequency Therapeutics Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MAIA | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 169.2 K | 154.9 K | 960.4 K | 1.2 M | 1.6 M | 899.5 K |
| ARMP | 600 K | 1.9 M | 1.9 M | 2.1 M | 1.5 M | 1.5 M | 1.7 M | 578 K | 729 K | 547 K | 956 K | 1.1 M | 1.7 M | 1.6 M | 1.3 M |
| PRTG | 41.1 K | 446.9 K | 446.9 K | 192 K | 620.6 K | 299.7 K | 109.1 K | 127 K | 388 K | 343 K | 113 K | 188 K | 274 K | 482 K | 304.4 K |
| CVKD | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 404.9 K | 167.3 K | 228.9 K |
| ICCC | 300 K | 149.9 K | 228.7 K | 152.2 K | 456.2 K | 200.6 K | 1.5 M | 1.2 M | 603.7 K | 572.2 K | 602.3 K | 745 K | 790 K | 874.6 K | 918.3 K |
| REPL | 323 K | 323 K | 323 K | 323 K | 323 K | 323 K | 323 K | 2 M | 7.1 M | 3.4 M | 2.4 M | 3.7 M | 5.4 M | 2.6 M | 3.7 M |
| NVCT | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 1.1 M | 2.9 M | 2.8 M | 1.9 M |
| LYRA | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 631 K | 1.1 M | 922 K | 3.1 M | 2.6 M | 3.1 M | 2.1 M |
| KRON | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 777 K | 1.5 M | 4.5 M | 998 K | 5 M | 883 K | 838.9 K |
| GOSS | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 40 K | 97 K | 2.2 M | 956 K | 7.5 M | 3.2 M | 1.5 M | 5.5 M | 2.9 M |
| NUVB | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 2 M | 2.2 M | 3.9 M | 2.1 M | 2.2 M | 2.3 M |
| OVID | 79.1 K | 79.1 K | 79.1 K | 79.1 K | 79.1 K | 670.5 K | 857.2 K | 2 M | 3.8 M | 3.3 M | 5.4 M | 7.1 M | 2 M | 3.7 M | 3.2 M |
| NXTC | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.5 M | 1.9 M | 3.9 M | 1.9 M | 4.3 M | 2.3 M | 2.8 M |
| CNTB | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 22.8 M | 3.8 M | 12.7 M | 11.9 M | 7.7 M | 8.3 M |
| SPRO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.1 M | 3.5 M | 3.6 M | 4.1 M | 1.2 M | 1.1 M | 617 K | 1.4 M | 1.6 M |
| BOLT | 892 K | 892 K | 892 K | 892 K | 892 K | 892 K | 892 K | 892 K | 892 K | 2.1 M | 1.6 M | 3.6 M | 3.6 M | 3 M | 2.7 M |
| CHRS | 3.9 M | 3.9 M | 3.9 M | 3.7 M | 10.8 M | 29.5 M | 20.6 M | 15.7 M | 15.3 M | 26 M | 15.2 M | 16.2 M | 11.5 M | 35.2 M | 18.7 M |
Lineage Cell Therapeutics and related stocks such as MAIA Biotechnology, Armata Pharmaceuticals, and Frequency Therapeutics Accounts Payable description
An accounting item on the balance sheet that represents Lineage Cell obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lineage Cell Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Lineage Cell Therapeutics | LCTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NYSE MKT Exchange |
USD 0.61
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.